| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.48B | +18.8% |
| Gross profit | ¥0.07B | — |
| Operating income | ¥-0.01B | — |
| Net income | ¥-0.01B | — |
| Gross margin | 14.5% | Net margin -2.7% |
| Revenue Q/Q | +7.4% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.41B | 85.5% |
| R&D | ¥0.02B | 4.2% |
| SG&A | ¥0.03B | 7.2% |
| Tax & other | ¥0.00B | 0.0% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
冠昊生物 ・ 东宝生物 ・ 飞力达 ・ 瑞丰光电 ・ 佳云科技 ・ 瑞丰高材 ・ 迪安诊断 ・ ST天玑 ・ 宝莱特 ・ 融捷健康 ・ 新开普 ・ 依米康
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies